NOVARTIS PHARMA AG - Switzerland 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:500-600
Total Number of Projects:300-400
2019
Criterium:Position:
Overall Score:300-400
Total Number of Projects:200-300
2018
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:> 1000
Total Number of Projects:300-400
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2010
Criterium:Position:
Overall Score:300-400
Total Project Funding per Partner:500-600
Total Number of Projects:800-900
Total Project Funding:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2009
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:700-800
2008
Criterium:Position:
Overall Score:200-300
Total Project Funding per Partner:300-400
Total Number of Projects:400-500
Total Project Funding:300-400
Networking Rank (Reputation):500-600
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2022-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 58
As coordinator: 1
As participant: 57
Sole participant: 0
Coordinator / Participant Ratio: 0.02*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 64.149.386 0 4
2020 0 113.082.516 0 10
2019 0 202.037.250 0 15
2018 0 169.338.471 0 9
2017 0 86.418.205 0 8
2016 0 29.414.923 530.454 6
2015 24.331.609 3.950.971 0 1 1
2012 0 3.935.114 528.884 1
2011 0 4.246.947 244.781 1
2010 0 17.757.048 547.100 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
PFIZER LIMITED31
JANSSEN PHARMACEUTICA NV27
F HOFFMANNLA ROCHE22
SANOFIAVENTIS22
BAYER18
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD18
UCB BIOPHARMA16
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT15
KATHOLIEKE UNIVERSITEIT LEUVEN15
ELI LILLY AND COMPANY LIMITED14
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE14
ASTRAZENECA13
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG13
NOVO NORDISK12
TAKEDA DEVELOPMENT CENTRE EUROPE11
TAKEDA PHARMACEUTICALS INTERNATIONAL11
ABBVIE INC10
CHARITE UNIVERSITAETSMEDIZIN BERLIN10
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM10
KING'S COLLEGE LONDON10
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN10
UNIVERSITAIR MEDISCH CENTRUM UTRECHT10
UNIVERSITY OF NEWCASTLE UPON TYNE10
KAROLINSKA INSTITUTE9
UPPSALA UNIVERSITET9
FORUM DES PATIENTS EUROPEENS8
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V8
MERCK SHARP & DOHME CORP8
STICHTING VUMC8
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL8
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS7
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS7
MEDIZINISCHE UNIVERSITAET WIEN7
RIJKSUNIVERSITEIT GRONINGEN7
TEVA PHARMACEUTICAL INDUSTRIES LIMITED7
THE UNIVERSITY OF MANCHESTER7
UNIVERSITY OF CAMBRIDGE7
UNIVERSITY OF COPENHAGEN7
ACADEMISCH ZIEKENHUIS GRONINGEN6
INSTITUT DE RECHERCHES SERVIER6
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN6
OSPEDALE PEDIATRICO BAMBINO GESU6
SERVICIO MADRILENO DE SALUD6
STICHTING KATHOLIEKE UNIVERSITEIT6
STICHTING LYGATURE6
THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA6
THE UNIVERSITY OF LIVERPOOL6
UNIVERSITY COLLEGE LONDON6
UNIVERSITY OF AARHUS6
UNIVERSITY OF DUNDEE6
VIB VZW6
ACADEMIC MEDICAL CENTRE AMSTERDAM5
BRISTOLMYERS SQUIBB COMPANY CORP5
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL5
ELI LILLY AND COMPANY5
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE5
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA5
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE5
LEIDS UNIVERSITAIR MEDISCH CENTRUM5
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE5
THE HYVE BV5
THE UNIVERSITY OF EDINBURGH5
THE UNIVERSITY OF SHEFFIELD5
UNIVERSITAET BERN5
UNIVERSITE DU LUXEMBOURG5
UNIVERSITY COLLEGE DUBLIN5
UNIVERSITY OF BOLOGNA5
UNIVERSITY OF HELSINKI5
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS4
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN4
ALZHEIMER EUROPE4
ASTELLAS PHARMA EUROPE BV4
ASTRAZENECA AB4
BAYER AKTIENGESELLSCHAFT4
CELGENE MANAGEMENT SARL4
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS4
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE4
COMMISSARIAT A L'ENERGIE ATOMIQUE4
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK4
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS4
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE4
EUROPEAN MOLECULAR BIOLOGY LABORATORY4
GRUNENTHAL4
H LUNDBECK AS4
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE4
INSTITUT PASTEUR4
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV4
MEDIZINISCHE HOCHSCHULE HANNOVER4
REGION HOVEDSTADEN4
STICHTING RADBOUD UNIVERSITEIT4
TEAM IT RESEARCH SL4
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE4
THE UNIVERSITY OF EXETER4
UNIVERSITA VITASALUTE SAN RAFFAELE4
UNIVERSITAET ULM4
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANSUNIVERSITAT4
UNIVERSITAT WIEN4
UNIVERSITATSKLINIKUM ERLANGEN4
UNIVERSITY OF BIRMINGHAM4
UNIVERSITY OF OSLO4

Constancy:

Total number of partners: 1619
Partner loyalty:
Frequent Partner: (> 2 projects): 879
Rare Partner: 740
Frequent / Rare Partner Ratio: 1.19

Project overview:

Start dateProjectacronymrolefundingpartners
2021-11-01European platform for neurodegenerative disorders EPNDparticipant9.680.00029
2021-10-01Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies SCREEN4CAREparticipant11.938.56937
2021-07-01Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States HIPPOCRATESparticipant10.210.99327
2021-02-01Central Repository for Digital Pathology BIGPICTUREparticipant32.319.82551
2020-11-01Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment Gravitate-Healthparticipant9.280.00042
2020-11-01Accelerating Research & Development for Advanced Therapies ARDATparticipant11.773.00034
2020-10-01HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS HARMONY PLUSparticipant6.715.62541
2020-10-01H2O Health Outcomes Observatory H2Oparticipant10.476.68725
2020-09-01Prioritisation and Risk Evaluation of Medicines in the EnviRonment PREMIERparticipant4.550.00025
2020-07-01C-H Activation for Industrial Renewal CHAIRparticipant3.938.27014
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05541
2020-04-01Corona Accelerated R&D in Europe CAREparticipant36.559.18642
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69429
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00028
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95337
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00023
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99833
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-04-01Biomarkers in Atopic Dermatitis and Psoriasis BIOMAPparticipant10.500.00032
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89735
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99829
2019-01-01Remote Assessment of Disease and Relapse – Alzheimer’s Disease RADAR-ADparticipant4.999.75717
2019-01-01NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients NECESSITYparticipant8.200.00025
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2019-01-01Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain IM2PACTparticipant9.000.00027
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-10-01Peroxisome Interactions and Communication PERICOparticipant3.974.52715
2018-09-01Ensuring the future of EUPATI beyond 2020 EFOEUPATIparticipant365.24312
2018-09-01WEB-RADR 2 WEB-RADR 2participant1.168.75012
2018-07-01Research empowerment on solute carriers (ReSOLUTE) ReSOLUTEparticipant12.000.00014
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00047
2018-04-01Improving the care of patients suffering from acute or chronic pain IMI-PainCareparticipant11.225.27140
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93135
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-03-01Big Data 4 Better Hearts - Sofia ref.: 116074 BigData Heartparticipant9.664.97019
2017-03-01Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 IMPRiNDparticipant4.684.99819
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-03-01Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases CaSR Biomedicineparticipant3.657.19518

overview shows latest 50 from 58 projects (2010-01-01 - 2022-12-31)
A full list of projects can be found here:

Alias institution names:

  • NOVARTIS PHARMA